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Considerable knowledge has recently accumulated on the mechanisms bywhich Helicobacter
pylon (H. pylon) induces chronic gastritis. Although H. pylon is not an invasive bacterium,
soluble surface constituents can provoke pepsinogen release from gastric chief cells or trigger
local inflammation in the underlying tissue. Urease appears to be one of the prime chemoat-
tractants for recruitment and activation of inflammatory cells. Release of cytokines, such as
tumor necrosis factor alpha, interleukin 1 and 6, and oxygen radicals, leads to a further tissue
inflammation accompanied by a potent systemic IgA and IgG type of immune response.
Chronic inflammation and antigens on glandular epithelial cells lead to a progressive destruc-
tion with loss ofthe epithelial barrier function. Within the gastric mucosa, patches ofintestinal
metaplasia develop, which may be a risk factor for subsequent development of gastric
carcinoma. Hyperacidity in duodenal ulcer patients induces gastric metaplasia in the duodenal
bulb, which represents a target forH.pylon colonization and ulcer formation.
H. pylon can be detected in the majority of patients with peptic ulcers and, compared to
age-matched healthy people, it is also found more often in patients with dyspepsia and gastric
carcinoma. Although H. pylon can be detected in healthy people, the marked reduction of the
ulcer recurrence rate by eradication of H. pylon (80 percent versus 20 percent relapse within
one year) suggests that H. pylon is a major risk factor for duodenal ulcer formation. The
potential role ofH.pylon in non-ulcer dyspepsia and carcinogenesis is under investigation.
Current regimens aimed at eradicating H. pylon use a combination of several drugs that are
potentially toxic. Since the risk of complications may exceed the potential benefit in most
patients, eradication treatment should be limited to clinical trials and to patients with
aggressive ulcer disease. New drug regimens, e.g., the combination of proton pump inhibitors
with one antibiotic, may provide less toxic alternatives. Beyond ulcer treatment, effective and
well-tolerated eradication regimens may have a place in prophylaxis ofgastric carcinoma.
INTRODUCTION
Our knowledge about the pathogenesis of the major gastric disorders such as
peptic ulcer disease and gastric malignancy is still very fragmentary. The extensive
research which has evolved since the first reports ofWarren [1] and Marshall [2], in
the early 1980s, on gastric colonization byCampylobacterpyloridis, now referred to as
Helicobacterpylori (H. pylon), has partly unraveled a few hitherto poorly understood
phenomena accompanying gastric pathology, but has also raised many new ques-
tions. It is nowwell established thatH.pylon colonizations represents one ofthe most
widespread human infections. It occurs worldwide, with considerable variation,
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depending on hygienic standards. The latter also influences the time of onset, which
is considerably earlier in underdeveloped countries. In the industrialized world,
approximately 50 percent of people above the age of 60 are infected [3]. It is now
widely accepted that H. pylon infection is the most important cause of gastritis [1,4]
and that it is strongly associated with peptic ulcer disease [5] and gastric cancer [6].
The majority ofsubjects infected do, however, never develop a peptic ulcer or gastric
malignancy, indicating that H. pylon infection does not represent more than a
co-factor in the pathogenesis ofboth diseases.
Little is known of the source and the spread ofH.pylon. It appears to be a primate
pathogen, since it has been detected mainly in humans and rhesus monkeys [7].
Based on endoscopic and serological data offamily members, direct transmission by
contact has been proposed [8,9]. Unique properties ofH. pylon such as its ability to
alter gastric mucus or to induce structural changes of epithelial cells, as well as
several clinical observations demonstrating the induction of gastritis in human
volunteers and a therapeutic effect of eradication of the bacteria, indicate that H.
pylon plays a major role in the pathogenesis of gastroduodenal diseases [10]. This
review is focused on the current knowledge of the pathophysiological mechanisms
and the clinical relevance ofH. pylon.
PATHOPHYSIOLOGICAL MECHANISMS
H. pylori Discovery: More Questions thanAnswers
H. pyloni is a gram-negative, curved, S-shaped, or spiral bacillus with one to five
sheathed unipolar flagellae. Its length is approximately 2.5-3.5,um, its diameter
0.5-1.0 ,um. Discovery of H. pylon has given a clear answer as to why patients
suffering from peptic ulcer disease in general have an increased ammonia concentra-
tion in the gastric juice. While this condition was initially attributed to urease
production by gastric epithelial cells [11], the fact is now well established that it is
caused by the almost ubiquitous colonization of the stomachs of these patients by H.
pyloni, a bacterium with high urease activity which splits urea to ammonia [12]. The
high urease activity facilitates detection of this organism. There are now a variety of
direct and indirect diagnostic tests available for the detection of this bacterium, but
H. pylon culture still represents the gold standard. Detection based on staining of
histological sections or determination of urease activity in mucosal biopsies yields
highly specific results, but the sensitivity varies between 69 and 100 percent [13,14].
The high urease activity ofH.pylon allowed the development ofbreath tests based on
hydrolysis of urea labeled with carbon isotopes 13C and 14C [15]. During hydrolysis,
CO2 is produced and can be recovered from the expired air as measurable 13CO2 or
14CO2. Breath tests have a sensitivity of about 90 percent and a specificity that varies
between 90-94 percent [16,17]. A series of serological tests has also been developed,
and several ELISAs based on sonicated and acid-extracted antigens from H. pyloni
are commercially available. Their sensitivity and specificity vary considerably, but,
with newer techniques utilizing purified antigens, both parameters are close to 100
percent [18]. These sereological tests are particularly useful for screening. They do,
however, not reflect the actual inflammatory activity in the gastric mucosa and tend
to fall only after three or more months following successful eradication of H. pylon
[19,20].
It is now proven beyond doubt that H.pylori is the principal cause ofthe so-called
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type B gastritis [4] and that it is an important co-factor in associated diseases,
including gastric malignancy. The discovery of H. pylon has changed the previous
concept that duodeno-gastric reflux is the main cause of the gastritis found in ulcer
patients. Indeed, duodeno-gastric reflux can today at best be considered as a
co-factor of H. pylon-induced damage of the gastric mucosa, especially in reflux
gastritis following gastric surgery. H. pylon is mainly found in gastric mucus and at
intercellular junctions. It only rarely invades epithelial cells [21], and it was initially
considered by many as an innocent bystander in previously damaged mucosa. From
many incidental observations, including those made on two human subjects who
intentionally ingested H. pylon [22,23], it is, however, now well established that
followingH. pylon infection the gastric mucosa is infiltrated with inflammatory cells,
including neutrophils, eosinophils, basophils, macrophages, monocytes, plasma cells,
and mast cells. The inflammatory response is accompanied by a substantial systemic
IgA and IgG antibody response, which is the proof that H. pylon is not simply a
commensal organism [4]. Despite this immunologically hostile microenvironment, H.
pylon appears to persist lifelong [24]. The presence of specific antibodies does not
even protect against recurrence of infection after a temporary clearance [24]. This
fact suggests that the organism is either inaccessible to the host immune response or
that the responses are rendered ineffective. It is now well established that type B
gastritis is largely reversible, following eradication of H. pylon at any stage of the
infection [9,25]. It has also been shown that H. pylon can causally elevate plasma
gastrin [26]. The original concept that the ammonia produced by H. pylon urease
neutralizes gastric acid and therefore interferes with the acid-gastrin feedback is
probably an oversimplification [27,28]. Of special interest are recent observations
suggesting that patients with H. pylon-associated gastritis have a selective suppres-
sion ofthe D cellswith subsequent loss ofthe normal inhibition ofD cells on G cells
[29-31]. H. pylon is also responsible for elevation of serum pepsinogen I levels in
duodenal ulcer disease [32] because, similar to gastrin levels, those of pepsinogen
can be reversed to control levels following H. pylon eradication. In contrast, neither
maximum acid output nor the sensitivity of the parietal cell to gastrin appears to be
influenced byH.pylon [33].
Mechanisms by Which H. pylori Damages Gastric Mucosa
Of particular interest are the mechanisms by which H. pylon damages gastric
mucosa. Locomotion is presumably required to allow H. pylon to move from the
gastric lumen into the viscous environment of gastric mucus [34]. Curved bacteria
have been detected within the phagocytic vacuoles of neutrophils located between
gastric epithelial cells, but invasion of H. pylon below the basal membrane has not
been observed [35]. These findings suggest that H. pylon recruits inflammatory cells
by releasing cell components or by shedding membrane components which, after
absorption into the mucosa, attract and activate leukocytes, monocytes, and macro-
phages (Fig. 1). Among the surface proteins, purified H. pylon urease has been
identified as an activator of leukocytes [35]. Like other gram-negative bacteria, H.
pylori contains lipopolysaccharides (LPS) and N-formylated oligopeptides (FMLP),
which are both potent chemotactic agents [36]. They stimulate monocytes and
macrophages which then release cytokines, such as tumor necrosis factor (TNF
alpha) and interleukins (IL-1 and -6), and oxygen radicals, such as superoxide anions
(02) [36-38]. All these cell products and probably additional unknown factors lead
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to recruitment and activation of inflammatory cells, tissue inflammation, and tissue
injury. These in vitro findings help to explain the histopathological observation ofH.
pyloni-associated gastritis.
Bacterial LPS appear to be strategic in pepsinogen stimulation. As recently shown
by Young and co-workers, H. pylon LPS induced a fiftyfold increase of pepsinogen
secretion, whereas E. coli LPS produced a much lower response [39]. An increase of
pepsin secretion was also observed when isolated glands from rabbit gastric mucosa
were exposed to a sonicatedH.pyloripreparation [40]. These in vitro findings support
the hypothesis that elevated serum pepsinogen I levels in patients with duodenal
ulcer disease are due to H. pyloni infection. The stimulation of pepsin secretion
appears to be an additional mechanism by which H. pylon produces mucosal injury
(Fig. 1).
A pathogenetic role has been proposed for several other virulence factors includ-
ing catalase, phospholipase, adhesins, and cytotoxin [41]. When exposed to cultured
epithelial cells, culture filtrates fromH.pylori strains found inpatientswith duodenal
ulcer produced intracytoplasmatic vacuoles, whereas culture filtrates from H. pylon
strains found in non-ulcer patients produced less cytotoxic effects [42]. Final proof
whether such factors modulate the virulence of H. pyloni strains might come from
manipulation of the H. pyloni genome [43]. Identification of virulence factors is
limited by the lackofsatisfactory animal models ofH.pyloni infection.
H. pylori: Degree andExtension ofGastnitis
H. pyloni-induced chronic inflammation of the gastric mucosa has important
cellular consequences. In acute type B gastritis, polymorph leukocytes tend to
congregate specifically around the gland neck. The damage to the stem cells located
at this site may provoke an increased cell turnover, as observed in chronic gastritis.
Although mucosal injury appears to induce secretion of mitogenic factors, such as
epidermal growth factor (EGF), preliminary in vitro experiments indicate that H.
pyloni inhibits EGF-stimulated epithelial cell proliferation [44-50]. The interaction
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between H. pylon and mucosal growth factors is largely unknown and needs further
investigation [51].
Various degrees of antral and body gastritis may develop over time, and it is well
established that, inpatientswith type B gastritis, mucosal atrophyincreaseswith age.
It appears that secondary immunological damage contributes to tissue destruction.
Antibodies produced against H. pylori are common but are not effective in the
defense against the bacillus. Moreover, it appears that the antibodies against H.
pylon cross-react with the antigens on glandular epithelial cells, leading to destruc-
tion of the epithelial structure and loss of the epithelial barrier function [52].
Glandular atrophy mainly affects gastric mucosa ofthe body and, over the years, the
corpus-antrum border moves proximally [53]. Extension of gastritis leads to a
decreased acid secretory capacity of the stomach, which may explain the "burnout
phenomenon" ofpepticulcerdisease [54,5]. It appears, however, that the continuous
advancement ofgastritis from the antrum to thebody and fundus ismore afeature of
gastric than ofduodenal ulcer disease [55].
Patches of intestinal metaplasia (IM) are common in chronic atrophic gastritis.
Since IM is found in many patients with gastric cancer, especially the intestinal type
of adenocarcinoma, it has been concluded that IM represents a pre-malignant
condition [56]. The notion that H. pylon may, at least in part, be responsible for IM
comes from observations made on dyspepticpatients inwhom IMwas more frequent
in H. pylon-infected subjects. H. pylon does not, however, adhere to metaplastic
areas, and it isthuspossible that intestinalmetaplasia represents a defense response;
i.e., replacement of gastric epithelium by an epithelium which is less susceptible to
chronic injury. A less pronounced inflammation was indeed found in the lamina
propria below patches ofintestinal metaplasia [57-59]. It is likely that the metaplas-
ticepithelium does not presentantigenicmaterial to the same degree asthe inflamed
H. pylon-positive gastric epithelium, and this possibility may be a reason why
"end-stage" gastritis often becomes H. pylon-negative. The question remains open
whether different strains ofH.pylon vary in their damaging effect ongastric mucosa,
e.g., why two-thirds of H. pylon strains isolated from patients with peptic ulcers
produce a cytotoxin, while this condition was found in only 30 percent of patients
without ulcers [41].
Gastric metaplasia (GM), i.e., gastric-type epithelium within the duodenal bulb
mucosa, is common in patients with duodenal ulcer disease. It is mainly found in the
first part of the duodenum but may extend to the second part in patients with
extensive involvement [59]. Gastric metaplasia is closely related to a low pH in the
fasting gastric juice [59]. Since duodenal ulcer disease is generally accompanied by
gastric hyperacidity, it is likely that gastric metaplasia develops as a result of
increased acid delivery from the stomach. Organisms passing into the duodenum
from the infected gastric mucosa may infect the metaplastic areas and provoke an
inflammatory cell response. The resultant cytotoxic injury reduces mucosal resis-
tance below a critical level so that acid-pepsin exposure leads to erosive and
ulcerative damage. H. pylon has a predilection for gastric-type epithelium. Whether
found in the stomach, the duodenum, or in Barrett's esophagus [60], only gastric
epithelial cells appear to possess receptor sites capable of binding the bacterial
attachment molecules or ligands. Thus, there is a direct sequence of events from H.
pylori-induced cellular injury through diminished mucosal defense and enhanced
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mucosal susceptibility to injurious agents (e.g., acid, pepsin, drugs like non-steroidal
inflammatory agents) to mucosal erosion or ulcers.
CLINICAL RELEVANCE OF H. PYLORI
Peptic UlcerDisease
The possibility that H. pyloni is the sole cause of duodenal ulcer is far from being
established. Infection with H. pylori in the presence of normal gastric acid secretion
is, however, considered to be the most important factor in the etiology of duodenal
ulcer disease. Close to 100 percent of all patients suffering from duodenal ulcer, and
some 80 percent of those with gastric ulcer, harbor this infectious agent in their
stomachs. Nevertheless, despite H. pyloni infection, most ulcers heal if treated with
potent inhibitors of gastric acid secretion such as H2-receptor antagonists or proton
pump inhibitors, andchronic use ofthe same drugs is effective for prevention ofulcer
relapse. The main clinical implication ofH. pyloni infection comes from the observa-
tion that eradication ofH. pylori currently represents the only treatment modality to
keep duodenal ulcers healed. This fact would make prophylactic use of acid-
inhibiting drugs or surgery unnecessary in most cases. Eradication of H. pyloni,
defined as absence ofH.pylori infection one month after the end oftreatment, leads
to a long-term remission, whereas the relapse rate of duodenal ulcers is 70-80
percent if H. pylor is not eradicated [61]. From studies performed before H.pylori
was identified, it is well known that the recurrence rate was smaller in patients
treated with colloidal bismuth as compared to those treated with H2-receptor
antagonists [61-63]. When bismuth was subsequently found to suppress H. pyloni, it
was hypothesized that the therapeutic gain resulting from bismuth was related to the
eradication ofH. pyloni.
Bismuth alone, however, suppresses H. pylori only temporarily [64], and more
aggressive therapeutic regimens, generally athree-drug combination ofbismuth with
metronidazole and an additional antibiotic such as tetracycline, amoxycillin, or
erythromycin, given for two to four weeks, yields the best eradication rates of 80-90
percent (Table 1). Complete eradication of H. pylori will keep approximately
four-fifths of all ulcers healed for several years, whereas only one-fourth to one-fifth
of the patients without antimicrobial therapy or failed eradication attempt remain
relapse-free [65-72].
Arguments against ageneral propagation ofthe rather cumbersome and expensive
multi-drug therapy are difficulties with patient compliance, emergence of resistant
strains, and potentially dangerous side effects such as diarrhea or Clostridium
difficile-associated colitis. Therefore, we currently limit treatment of H. pyloni to
patients with complicated or recurrent peptic ulcer disease.
In an attempt tomake treatment ofH.pylori more acceptable to the patient, Logan
et al. developed a one-week treatment regimen consisting of tripotassium dicitrato
bismuthate, amoxycillin, and metronidazole [73] (Table 1). This regimen yielded an
eradication rate of72 percent (median follow-up, 9.3 months), and the best eradica-
tion rate was found in patients with metronidazole-sensitive H. pylori strains (93
percent). Recently it has become apparent that the proton pump inhibitor omepra-
zole possesses antimicrobial activity in vitro. Given in mono-therapy, omeprazole
could suppress but not eradicate H. pylon infection (Table 2) [74-77,79]. Combined
with amoxycillin, eradication rates rose to 82 percent [78,79], which makes this
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TABLE 1
Standard Triple Therapy and Eradication ofHelicobacterpylori
No. of Drug Combination Eradication
Author [Ref.] Patients (dose/duration) (%)
Marshall et al. [67] 22 Cimetidine/placebo 0
1988 29 Cimetidine/tinidazole 4
22 CBS/placebo 27
27 CBS, 1 tablet qds/8 weeks
Tinidazole, 500 mg bid/day 1-10 74
Ifsensitive to tinidazole 85
Borody et al. [69] 100 Tripotassium dicitrato
1988 bismuthate, qds/4 weeks
Tetracycline, 500 mg qds/4weeks
Metronidazole, 200 mg qds/2 weeks 94
Rauws and Tytgat [71] 26 CBS, 1 tablet qds/4 weeks 10
1990
24 CBS, 1 tablet qds/4 weeks
Amoxicillin, 350 mg tds/4 weeks
Metronidazole, 500 mg tds/day 18-28 88
Logan et al. [73] 106 Tripotassium dicitrato 72
1991 bismuthate, 120 mg qds/1 week
Amoxicillin, 500 mg qds/1 week
Metronidazole, 400 mg x 5/day 5-7
Metronidazole-sensitive 93
CBS, colloidal bismuth subcitrate
treatment regimen an acceptable alternative. These results are based on small
patient groups and need further confirmation.
Non-UlcerDyspepsia
It has long been debated whether chronic gastritis is responsible for dyspeptic
symptoms [80]. Studies performed before the recognition ofH. pylori have generally
yielded a negative result [81]. No satisfactory answer to the question whether H.
pylon infectionis more common inpatientswithchronicdyspepsiathanin asymptom-
atic subjects is currently available. This difficulty is related tovarious factors, such as
differences in classification of the degree ofgastritis, the increase of the prevalence
of H. pylon infection with age, and the wide variations of clinical symptomatology.
Several studies show a slight preponderance of infected individuals in the chronic
dyspepsia group comparedwith controls, but the difference is small [82].
Some investigators found that some symptoms like "burping" [83], postprandial
bloating [84,85], or epigastric burning and fullness [86] were found more often in H.
pylon-positive dyspeptic patients. In contrast, no significant differences in symptoms
could be found between H. pylon-positive and H. pylon-negative patients in several
other studies [87-89]. It is thus likely that H. pylon infection does not cause a
constant and specific dyspeptic symptomatology. Indeed, very large population
631HALTER ET AL.
TABLE 2
Omeprazole and Eradication ofHelicobacterpylori
No. of Drug Combination Eradication
Author [Ref.] Patients (dose/duration) (%)
Unge et al. [74] 8 Omeprazole, 40 mgom/2weeks 0
1989
7 Amoxicillin, 750 mgbd/2weeks 14
8 Omeprazole, 40 mg om/2weeks
Amoxicillin, 750 mgbd/2weeks 63
De Koster et al. [75] 9 CBS, 120 mg qds/1 week
1991 Omeprazole, 40 mg om/1 week 0
18 CBS, 120 mg qds/1 week
Omeprazole, 40 mg om/1 week
Erythromycin, 500 mg qds/1 week 50
12 CBS, 120 mg qds/1 week
Omeprazole, 40 mg om/1 week
Amoxicillin, 500 mg qds/1 week
Minocyclin, 100 mg bd/1 week 50
Lamouliatte et al. [76] 20 Omeprazole, 20 mg daily/4 weeks
1991 Amoxicillin, 2 g daily/2 weeks
Tinidazole, 1 g daily for 10 days 90
20 Ranitidine, 300 mg daily/6 weeks
Amoxicillin, 2 g daily/2 weeks
Tinidazole, 1 g daily/2 weeks 80
Bell et al. [77] 16 Omeprazole, 20 mg at night/4 weeks
1991 Amoxicillin, syrup, 250 mg tds/2 weeks 31
14 Omeprazole, 20 mg at night/4 weeks
CBS, 240 mgbd/4 weeks 14
Bayesd6rffes et al. [79] 27 Omeprazole, 40 mg bd for 10 days 82
1992 Amoxicillin, 1 g bd for 10 days
followed by omeprazole, 20 mg daily/6 weeks
26 Omeprazole, 40 mg bd for 10 days 0
followed byomeprazole, 20 mg daily/6 weeks
CBS, colloidal bismuth subcitrate
samples would be necessary to confirm or refute the possibility of a specific H.
pylori-associated syndrome. Many clinicians consider routine biopsy sampling aimed
at identifying H. pylori infection in patients with common upper gastrointestinal
symptoms as premature, since the risk ofcomplications from the current multi-drug
regimen maywell exceed the potential benefits.
GastricMalignancy
Recently, evidence has accumulated that H. pylori increases the risk of gastric
carcinoma [90-92,6]; it appears that population groups infected at an early age are
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particularly at risk [93-95]. In American men of Japanese ancestry in Hawaii,
affected with gastric carcinoma, the odds ratio ofhaving serum antibodies againstH.
pylon was 6.0 as compared to matched controlswithoutgastric tumor [92]. Neverthe-
less, most human subjects infected withH.pylori will not develop gastric cancer, and
there are even data indicating that the presence of a peptic ulcer protects patients
infected withH.pylori from developinggastric carcinoma [91]. It is therefore evident
that H. pylon is neither sufficient nor necessary for gastric carcinogenesis, and
environmental factors andcarcinogens are likelytobe important co-factors [96] (Fig.
2). There is circumstantial evidence that long-standing H. pylon infection predis-
poses to formation ofintestinal metaplasia. In a recent study including 533 subjects,
intestinal metaplasia was found in 135 patients (25 percent) and H. pylon in 289
patients (54 percent) [55]. Intestinal metaplasia was encountered more often in H.
pylon-positive patients as compared with H. pylon-negative subjects (34 percent
versus 15 percent,p < 0.001). The prevalence of intestinal metaplasia and H. pylon
was age-related, being more common in patients over 50 years as compared with
patients under 50 years. The mean age of patients with intestinal metaplasia who
were also H. pylon-positive was 64 years, whereas the mean age of patients with
intestinal metaplasia who wereH.pylon-negative was 72years (p < 0.005).
Screening for growth factor expression in gastric tissue may have a potential to
detect patients at risk. Immunohistochemical studies revealed an increase in expres-
sion of growth factors close to the proliferative zone in inflamed antral mucosa,
especially in H. pylon-positive patients [97]. Epidermal growth factor (EGF) may
have an oncogenic potential in the stomach [98,99]. EGF receptors have been
verified in a poorly differentiated gastric cancer cell line [100] and in surgically
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resected gastric carcinomas [101]. In this context, it would be ofinterest to compare
growth factor expression in different stages of intestinal metaplasia and to evaluate
whether this comparison could serve as a screening method in high-riskpatients.
Astill open question iswhyonly a small fraction ofsubjects infected withH.pylon
develop gastric cancer. It has been suggested that differences in the virulence ofH.
pylon strains might determine their carcinogenic potential [102]. A similar open
question iswhy, in some individuals, the lymphoid infiltrateswhich accumulate in the
gastric mucosa in response to H. pylon infection undergo malignant transformation
and develop to malignant lymphoma [103].
OUTLOOK
Progress on H. pylon is hampered by several shortcomings. Of particular impor-
tance are the lack ofa cheap small animal model, the lack ofmethods for identifying
H.pylon strains with different virulence, and the unavailability ofa simple non-toxic
therapeutic regimen for eradication ofH.pylon.
Current assay methods forH. pylon need to be improved. Progress is in sight with
regard to new assays based on in situ hybridization [104] or on the polymerase chain
reaction [105-107]. Once these molecular biology techniques are established as the
gold standard, both the sensitivity and specificity ofcurrent assay methods may have
to be revised. These new developments might also help to evaluate the existence of
particularlyvirulent strains.
From a clinical standpoint, the prospect of simpler and less toxic therapeutic
measures aimed at eradication ofH. pylon is of special importance. The promising
results obtained with a treatment regimen combining proton pump inhibitors with a
non-toxic antibiotic urgently need further confirmation and extension. A serological
test able to detect seroconversion to normal shortly after eradication of H. pylon
would greatly help to evaluate new treatment regimens.
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